Canine lymphoma (cL) is a common type of neoplasia in dogs with an estimated incidence
rate of 20–100 cases per 100,000 dogs and is in many respects comparable to non-Hodgkin …

Drug resistance (DR) is the major limiting factor in the successful treatment of systemic
neoplasia with cytotoxic chemotherapy. DR can be either intrinsic or acquired, and although …

Canine lymphoma is typically treated with a doxorubicin-based multidrug chemotherapy
protocol. Although this is often initially successful, tumour recurrence is common and …

Acquired chemoresistance during chemotherapy, often accompanied by cross-and multi-
resistance, limits therapeutic outcomes and leads to recurrence. In order to create in vitro …

Several classes of chemotherapy drugs are used as first line or adjuvant treatment of the
majority of tumour types in veterinary oncology. However, some types of tumour are …

Targeted next-generation sequencing (NGS) enables the identification of genomic variants
in cancer patients with high sensitivity at relatively low costs, and has thus opened the era to …

Transmissible venereal tumour (TVT) generally presents different degrees of
aggressiveness, which makes them unresponsive to conventional treatment protocols. This …

Background: Treatment of malignancies is still a major challenge in human and canine
cancer, mostly due to the emergence of multidrug resistance (MDR). One of the main …

Abstract Characterization and identification of cancer cell, chemotherapy, resistance is
important for both routine cancer therapy and trouble-shooting the medication treatment …

Corticosteroid administration prior to the application of chemotherapy in small animal
lymphoma patients is a concern, as it is discussed to negatively influence the therapeutic …